Impact of antimüllerian hormone assays on the outcomes of in vitro fertilization: a prospective controlled study

Aboulghar, Mohamed; Saber, Walid; Amin, Yehia; Serour, Gamal I.; Mansour, Ragaa

doi:10.1016/j.fertnstert.2013.09.028

Cited by 16 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Very low AMH levels correlate with a poor response to stimulation by exogenous gonadotropins and with a lower implant success rate in IVF. [31][32][33][34][35][36] Some studies indicate that women who are HCV+ exhibit poor ovarian response to exogenous stimulation and have high rates of complication, potentially favouring miscarriage. 34,35 In particular, women who are HCV+ display reduced rates of ovarian follicle development after stimulation, higher incidence of apoptosis, and reduced pregnancy rates compared with controls.…”

Section: Discussionmentioning

confidence: 99%

Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

Karampatou

Han

Kondili

et al. 2018

Journal of Hepatology

View full text Add to dashboard Cite

Most new cases of HCV infection are among people who inject drugs, many of whom are young women in their childbearing years. Women of reproductive age who are HCV+ display markers of ovarian senescence. This is associated with an increased burden in terms of infertility and adverse pregnancy outcomes, including stillbirth, miscarriage, fewer live births, and gestational diabetes. Early viral suppression with therapy is likely to mitigate these risks.

show abstract

Section: Discussionmentioning

confidence: 99%

Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

Karampatou

Han

Kondili

et al. 2018

Journal of Hepatology

View full text Add to dashboard Cite

show abstract

“…The criteria for cycle cancelation were the presence of less than three follicles with an E2 level less than 400 pg/ml. Women in group B n = 306 were treated with our routine long GnRH-a protocol which was published before [3].…”

Section: Methodsmentioning

confidence: 99%

“…In women, AMH is produced by the granulosa cells (GC) in the preantral and antral follicles [2]. Because serum AMH levels reflect the ovarian follicular pool, any reduction in the number of small, growing follicles may be followed by a reduction in the circulating AMH [3]. AMH is a better marker of the ovarian reserve than age alone and is superior to other markers described in the literature, such as basal FSH, E2, and inhibin B [4].…”

Section: Introductionmentioning

confidence: 99%

Live birth rate after IVF/ICSI in women with low and extremely low AMH: an age-matched controlled study

Zaghloul

Amin

Mansour

et al. 2020

Middle East Fertil Soc J

Self Cite

View full text Add to dashboard Cite

Background: An age-matched controlled study, to assess the outcome of IVF/ICSI in low and extremely low AMH levels in different age groups by comparing the live birth rate Materials and methods: An age-matched controlled study was done at the Egyptian IVF center, Cairo, Egypt, including 306 infertile women with low AMH levels undergoing IVF/ICSI and an age-matched number of women with normal AMH. The live birth rate in the different age groups according to the AMH level was compared. Results: There was no significant difference between LBR in the extremely low AMH arm (11.43%) and low AMH (16.4%) (P = 0.24). The LBR was 30.4% in women with normal AMH as compared to 14.7% in all women with AMH below 1 pg/ml (P = 0.002). The LBR was significantly higher in women below the age of 35 years and women of 35-40 years with normal AMH (33.2% and 31.7%) as compared to LBR in the corresponding age groups with low AMH (18.6% and 13.3%). Conclusions: There was no difference in the outcome of IVF between patients with low and extremely low AMH levels. Women with normal AMH level resulted in a higher pregnancy rate as compared to women with low AMH level in the same age group. Age is important in determining prognosis of IVF in patients with low levels of AMH.

show abstract

“…Recent research has targeted developing specific ovarian stimulation protocols individualized by AMH results [16 ▪▪ ,17 ▪ ]. Other recent studies focus on refining information such as demonstrating that an AMH value from a single point in time will remain predictive for approximately 12 months [18], how certain stimulation protocols affect different patient phenotypes such as PCOS vs. low responders [19 ▪▪ ,20], and prospectively demonstrating that application of AMH testing can improve expectation management and possibly treatment costs [21]. …”

Section: Oocyte Quantity and Quality Fertility Treatment And Naturamentioning

confidence: 99%

Maximizing the clinical utility of antimüllerian hormone testing in women's health

Leader¹,

Baker

2014

Current Opinion in Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Purpose of reviewTo provide an update on the latest clinical applications of serum antimüllerian hormone (AMH) testing with practical approaches to mitigate the impact of significant variability in AMH results.Recent findingsRecent studies continue to demonstrate that AMH is the best single serum test for ovarian response management with, at most, a weak-to-moderate age-independent association with live-birth rate and time to conception. Data confirm serum AMH levels improve menopause prediction, monitoring of ovarian damage, and identification of women at risk for several ovary-related disorders such as polycystic ovary syndrome and premature or primary ovarian insufficiency. However, it is now recognized that serum AMH results can have dramatic variability due to common, biologic fluctuations within some individuals, use of hormonal contraceptives or other medications, certain surgical procedures, specimen treatment, assay changes, and laboratory calibration differences. Practical guidelines are provided to minimize the impact of variability in AMH results and maximize the accuracy of clinical decision-making.SummaryAMH is an ovarian biomarker of central importance which improves the clinical management of women's health. However, with the simultaneous rapid expansion of AMH clinical applications and recognition of variability in AMH results, consensus regarding the clinical cutpoints is increasingly difficult. Therefore, a careful approach to AMH measurement and interpretation in clinical care is essential.

show abstract

Impact of antimüllerian hormone assays on the outcomes of in vitro fertilization: a prospective controlled study

Cited by 16 publications

References 20 publications

Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

Live birth rate after IVF/ICSI in women with low and extremely low AMH: an age-matched controlled study

Maximizing the clinical utility of antimüllerian hormone testing in women's health

Contact Info

Product

Resources

About